entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 17:44:48 - browse：3

Adam's take main illustration — Molly Ferguson/STAT

This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study.

A looming test for neoantigen cancer vaccines

Before the end of the quarter, Gritstone Bio will release preliminary results from a randomized, Phase 2 clinical trial investigating a personalized therapeutic cancer vaccine in microsatellite-stable colon cancer, a type of “immunologically cold” tumor that is resistant to immunotherapies like PD-1/PD-L1 inhibitors.

The Gritstone vaccine is designed to train a patient’s own T cells to recognize and kill cancer cells by targeting mutated cancer proteins, called neoantigens, that are unique to a patient’s own tumor. It’s a relatively new approach for cancer vaccines — made possible by powerful and relatively inexpensive genomic sequencing of tumors – that is intended to overcome all the previous failures in the field. Gritstone’s effort is also similar to one being used by Moderna and Merck that has reported encouraging results in melanoma — and is now being investigated in a Phase 3 study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： What to expect as Trump is arraigned on his Jan 6. indictment

WSS

No plane should take off without an EpiPen onboard

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

'Patient friction coefficient' can gauge a clinical trial's patient burden

This gene therapy has record $4.25 million price. It's saved children.

What the airline industry can learn from medicine

Wildfire pollution widens asthma inequities on Long Island

focus

entertainment

A looming test for neoantigen cancer vaccines

knowledge

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Adam's Take: Intra

New air purifier tech could be key to improving indoor air quality

Chinese researcher claims birth of first gene

Duchenne breakthrough therapy leaves behind pioneering families

‘Oppenheimer’ and the risks of AI in health care

DIEP, the 'gold standard' of breast reconstruction, is under threat

‘Oppenheimer’ and the risks of AI in health care

Novavax promises a turnaround & Lilly roils the obesity market

Biotech investment managers search for lucrative opportunities

hotspot

Trump indictment: Who are the 'co

What to expect as Trump is arraigned on his Jan 6. indictment

Mitch McConnell episode has important public health takeaway

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Biotech investment managers search for lucrative opportunities

EQRx, failed developer of low

focus

leisure time

entertainment

knowledge